WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/007552    International Application No.:    PCT/GB2003/003107
Publication Date: 22.01.2004 International Filing Date: 17.07.2003
A61K 38/00 (2006.01), C07K 14/715 (2006.01)
Applicants: ARES TRADING S.A. [CH/CH]; Chateau de Vaumarcus, CH-2028 Vaumarcus (CH) (For All Designated States Except US).
RODRIGUES, Tania, Maria [PT/GB]; (GB) (For US Only).
FAGAN, Richard, Joseph [US/GB]; (GB) (For US Only).
PHELPS, Christopher, Benjamin [GB/GB]; (GB) (For US Only).
POWER, Christine [GB/FR]; (FR) (For US Only)
Inventors: RODRIGUES, Tania, Maria; (GB).
FAGAN, Richard, Joseph; (GB).
PHELPS, Christopher, Benjamin; (GB).
POWER, Christine; (FR)
Agent: GOODFELLOW, Hugh, Robin; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB)
Priority Data:
0216661.9 17.07.2002 GB
Abstract: front page image
(EN)The invention is based on the discovery that the human protein referred to herein as INSP076 protein is a member of the cytokine receptor-type I family (hematopoietin receptor superfamily). Preferably, INSP076 functions as an IL-9 receptor or an IL-9 receptor-like protein. The INSP076 protein does not possess a transmembrane domain and accordingly the INSP076 protein is a potential soluble receptor. It is believed that the INSP076 protein may function as an IL-9 antagonist.
(FR)L'invention concerne la protéine humaine désignée ici sous le nom de protéine INSP076, un membre de la famille des récepteurs de cytokine de type I (superfamille des récepteurs d'hématopoïétine). L'INSP076 fonctionne, de préférence, comme un récepteur de l'IL-9 ou une protéine de type récepteur de l'IL-9. La protéine INSP076 ne possède pas de domaine transmembranaire et constitue, par conséquent, un récepteur soluble potentiel. La protéine INSP076 pourrait fonctionner en tant qu'antagoniste de l'IL-9.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)